TW200720252A - Cyclic amine derivative having substituted alkyl group - Google Patents

Cyclic amine derivative having substituted alkyl group

Info

Publication number
TW200720252A
TW200720252A TW095118701A TW95118701A TW200720252A TW 200720252 A TW200720252 A TW 200720252A TW 095118701 A TW095118701 A TW 095118701A TW 95118701 A TW95118701 A TW 95118701A TW 200720252 A TW200720252 A TW 200720252A
Authority
TW
Taiwan
Prior art keywords
group
alkyl group
alkyl
optionally substituted
substituted
Prior art date
Application number
TW095118701A
Other languages
English (en)
Inventor
Tomio Kimura
Naoki Tanaka
Hiroyuki Kobayashi
Atsuhiro Sugidachi
Original Assignee
Sankyo Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Co filed Critical Sankyo Co
Publication of TW200720252A publication Critical patent/TW200720252A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
TW095118701A 2005-05-27 2006-05-26 Cyclic amine derivative having substituted alkyl group TW200720252A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2005155009 2005-05-27

Publications (1)

Publication Number Publication Date
TW200720252A true TW200720252A (en) 2007-06-01

Family

ID=37452098

Family Applications (1)

Application Number Title Priority Date Filing Date
TW095118701A TW200720252A (en) 2005-05-27 2006-05-26 Cyclic amine derivative having substituted alkyl group

Country Status (13)

Country Link
EP (1) EP1889835A4 (zh)
JP (1) JPWO2006126676A1 (zh)
KR (1) KR20080013944A (zh)
CN (1) CN101233108A (zh)
AU (1) AU2006250335B2 (zh)
BR (1) BRPI0610311A2 (zh)
CA (1) CA2609852A1 (zh)
IL (1) IL187524A0 (zh)
NO (1) NO20076624L (zh)
RU (1) RU2382771C2 (zh)
TW (1) TW200720252A (zh)
WO (1) WO2006126676A1 (zh)
ZA (1) ZA200710172B (zh)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007001974A (ja) * 2005-05-27 2007-01-11 Sankyo Co Ltd ヘテロアリール環を有する環状アミン誘導体を含有する医薬組成物
US9303038B2 (en) 2011-09-06 2016-04-05 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy and neurological diseases
CA2873094A1 (en) * 2012-05-07 2013-11-14 Cellixbio Private Limited Prodrugs of anti-platelet agents
JP2015519333A (ja) 2012-05-07 2015-07-09 セリックスビオ プライヴェート リミテッド 神経疾患の治療のための組成物および方法
WO2013168021A1 (en) 2012-05-07 2013-11-14 Mahesh Kandula Compositions and methods for treatment of neuromuscular disorders and neurodegenerative disorders
US9266823B2 (en) 2012-05-08 2016-02-23 Cellix Bio Private Limited Compositions and methods for the treatment of parkinson's disease
WO2013168022A1 (en) * 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for treating atherothrombosis
US9403826B2 (en) 2012-05-08 2016-08-02 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory disorders
WO2013167991A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of metabolic disorders
US9309233B2 (en) 2012-05-08 2016-04-12 Cellix Bio Private Limited Compositions and methods for the treatment of blood clotting disorders
US9434704B2 (en) 2012-05-08 2016-09-06 Cellix Bio Private Limited Compositions and methods for the treatment of neurological degenerative disorders
US9394288B2 (en) 2012-05-10 2016-07-19 Cellix Bio Private Limited Compositions and methods for the treatment of asthma and allergy
WO2013168004A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of fibromyalgia pain
WO2013168016A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of metabolic syndrome
US9573927B2 (en) 2012-05-10 2017-02-21 Cellix Bio Private Limited Compositions and methods for the treatment of severe pain
WO2013167999A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurologic diseases
US9273061B2 (en) 2012-05-10 2016-03-01 Cellix Bio Private Limited Compositions and methods for the treatment of chronic pain
US9233161B2 (en) 2012-05-10 2016-01-12 Cellix Bio Private Limited Compositions and methods for the treatment of neurological conditions
US9321775B2 (en) 2012-05-10 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of moderate to severe pain
US9242939B2 (en) 2012-05-10 2016-01-26 Cellix Bio Private Limited Compositions and methods for the treatment of respiratory disorders
US9499526B2 (en) 2012-05-10 2016-11-22 Cellix Bio Private Limited Compositions and methods for the treatment of neurologic diseases
WO2013167997A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of metabolic syndrome
WO2013168014A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of familial amyloid polyneuropathy
US9339484B2 (en) 2012-05-10 2016-05-17 Cellix Bio Private Limited Compositions and methods for the treatment of restless leg syndrome and fibromyalgia
US9434729B2 (en) 2012-05-23 2016-09-06 Cellix Bio Private Limited Compositions and methods for the treatment of periodontitis and rheumatoid arthritis
CN104583182A (zh) 2012-05-23 2015-04-29 塞利克斯比奥私人有限公司 用于治疗粘膜炎的组合物和方法
US9492409B2 (en) 2012-05-23 2016-11-15 Cellix Bio Private Limited Compositions and methods for the treatment of local pain
WO2013175347A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of respiratory disorders
CA2873096A1 (en) 2012-05-23 2013-11-28 Cellixbio Private Limited Compositions and methods for the treatment of inflammatory bowel disease
US9108942B1 (en) 2014-11-05 2015-08-18 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
WO2014020480A2 (en) 2012-08-03 2014-02-06 Mahesh Kandula Compositions and methods for the treatment migraine and neurologic diseases
WO2014037833A2 (en) 2012-09-06 2014-03-13 Mahesh Kandula Compositions and methods for the treatment inflammation and lipid disorders
WO2014037834A2 (en) 2012-09-08 2014-03-13 Mahesh Kandula Compositions and methods for the treatment of inflammation and lipid disorders
US9718778B2 (en) * 2013-01-09 2017-08-01 The Regents Of The University Of Michigan Mixed disulfide conjugates of thienopyridine compounds and uses thereof
US9333187B1 (en) 2013-05-15 2016-05-10 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory bowel disease
WO2014195961A1 (en) 2013-06-04 2014-12-11 Mahesh Kandula Compositions and methods for the treatment of diabetes and pre-diabetes
US9096537B1 (en) 2014-12-31 2015-08-04 Mahesh Kandula Compositions and methods for the treatment of mucositis
CA2976314C (en) 2014-09-26 2021-02-23 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy and neurological disorders
ES2799309T3 (es) 2014-09-29 2020-12-16 Cellix Bio Private Ltd Compuestos y composiciones para el tratamiento de esclerosis múltiple
CA2965449C (en) 2014-10-27 2020-11-10 Cellix Bio Private Limited Three component salts of fumaric acid monomethyl ester with piperazine or ethylene diamine for the treatment of multiple sclerosis
US10208014B2 (en) 2014-11-05 2019-02-19 Cellix Bio Private Limited Compositions and methods for the treatment of neurological disorders
US9321716B1 (en) 2014-11-05 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
US9284287B1 (en) 2014-11-05 2016-03-15 Cellix Bio Private Limited Compositions and methods for the suppression of carbonic anhydrase activity
US9290486B1 (en) 2014-11-05 2016-03-22 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy
US9173877B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Compositions and methods for the treatment of local pain
US9175008B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Prodrugs of anti-platelet agents
US9150557B1 (en) 2014-11-05 2015-10-06 Cellix Bio Private Limited Compositions and methods for the treatment of hyperglycemia
US9932294B2 (en) 2014-12-01 2018-04-03 Cellix Bio Private Limited Compositions and methods for the treatment of multiple sclerosis
US9206111B1 (en) 2014-12-17 2015-12-08 Cellix Bio Private Limited Compositions and methods for the treatment of neurological diseases
CN107428697A (zh) 2015-01-06 2017-12-01 塞尔利克斯生物私人有限公司 用于治疗炎症和疼痛的组合物和方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3274088B2 (ja) * 1996-08-28 2002-04-15 三共株式会社 環状アミン誘導体
NZ334389A (en) * 1996-08-28 2001-05-25 Ube Industries Cyclic amine derivatives
ID25589A (id) * 1998-02-27 2000-10-19 Sankyo Company Ltd Cs Senyawa-senyawa amino siklik
JP3907029B2 (ja) * 1998-02-27 2007-04-18 三共株式会社 環状アミン誘導体を含有する医薬
JP3856185B2 (ja) * 1998-02-27 2006-12-13 三共株式会社 環状アミノ化合物
WO2005051913A1 (ja) * 2003-11-28 2005-06-09 Sankyo Company, Limited ヘテロアリール環を有する環状アミン誘導体

Also Published As

Publication number Publication date
NO20076624L (no) 2008-02-26
AU2006250335B2 (en) 2010-09-02
CN101233108A (zh) 2008-07-30
KR20080013944A (ko) 2008-02-13
RU2382771C2 (ru) 2010-02-27
JPWO2006126676A1 (ja) 2008-12-25
ZA200710172B (en) 2008-11-26
EP1889835A1 (en) 2008-02-20
AU2006250335A1 (en) 2006-11-30
EP1889835A4 (en) 2010-04-28
CA2609852A1 (en) 2006-11-30
BRPI0610311A2 (pt) 2010-06-15
RU2007149317A (ru) 2009-07-10
IL187524A0 (en) 2008-03-20
WO2006126676A1 (ja) 2006-11-30

Similar Documents

Publication Publication Date Title
TW200720252A (en) Cyclic amine derivative having substituted alkyl group
MX344669B (es) Agente antiplaquetas novedoso.
PT1625126E (pt) Imidazo- e tiazolopiridinas como inibidores de cinase jak3
MY141255A (en) Phosphodiesterase 4 inhibitors, including n-substituted diarylamine analogs
WO2008108380A3 (en) Pyrrole compounds
MX2008014908A (es) Compuesto heterociclico nuevo o sal del mismo e intermedio del mismo.
MX2011009034A (es) Formas de profarmaco de inhibidores de cinasa y su uso en la terapia.
MX2010003156A (es) Derivados de aril amida substituida con tetrazol y usos de los mismos.
MX2010003155A (es) Derivados de ciclopropil aril amida y uso de los mismos.
HK1110588A1 (en) Novel phenylaminopyrimidine derivatives as inhibitors of bcr-abl kinase
MX2010009752A (es) Compuestos de oxadiazoantraceno para el tratamiento de diabetes.
MY151986A (en) Adamantyl diamide derivatives and uses of same
TW200500339A (en) Pyrrolidine derivatives, and process for the preparation
MXPA05010440A (es) Amidas del acido isoquinolina-5-sulfonico como inhibidores de la akt (proteina quinasa b).
WO2010003084A3 (en) Phosphodiesterase 4 inhibitors
TW200508215A (en) Cyclic tertiary amine compounds
TW200621785A (en) Analgesic
ATE488510T1 (de) Heterocyclische derivate, deren herstellung und therapeutische verwendung
MY138466A (en) Aminoalkoxyndoles as 5-ht6-receptor ligands for the treatment of cns-disorders
NO20070550L (no) Fremgangsmate for fremstilling av pyrrolotriazinforbindelser
PL1845780T3 (pl) Zastosowanie pochodnych metylofenidatu
NO20061344L (no) Imidazopyridinderivater som induserbare NO-syntaseoinhibitorer
DE60314381D1 (de) Benzylimidazolyl substituierte 2-chinolon und chinazolinon derivate zur verwendung als farnesyl transferase inhibitoren
FR2894579B1 (fr) Derives diaryltriazolmethylamine, leur preparation et leur application en therapeutique.
EA200600601A1 (ru) Производные аминопиридина в качестве ингибиторов индуцируемой no-синтазы